Metformina + Sitagliptina Polpharma

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Polpharma, is a biguanide and DPP‑4 inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used in combination with diet and exercise.

GNH USA supplies Metformina + Sitagliptina Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under GMP conditions.

Metformina + Sitagliptina Polpharma is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose levels. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to other antidiabetic agents. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise measures to achieve target HbA1c.

Metformina + Sitagliptina Polpharma may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild persistent headache. - Upper respiratory tract infection: cold‑like symptoms. - Decreased appetite: reduced food intake.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic condition. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes. - Skin reactions: rash or Stevens‑Johnson syndrome. - Renal impairment: worsening kidney function.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic disease evaluation: use cautiously in liver disease. - Cardiovascular status: monitor for heart failure symptoms. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Concomitant medications: review for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina Polpharma can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: risk of acute renal failure; discontinue metformin before and after imaging. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Insulin or sulfonylureas: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (loop or thiazide): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: increases risk of lactic acidosis. - Beta‑blockers: may mask hypoglycaemia symptoms.